(Reuters) - Angel Perez-Agenjo, Eli Lilly director for Denmark and Iceland, said the side-effects of Zyprexa had been reported extensively and that the FDA had been provided with all the data.
"We are working very closely with the FDA on Zyprexa as we are doing with any other product," he told Reuters in connection with the launch of Lilly's Byetta type 2 diabetes drug.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment